Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management

Liver Transplantation

Volumn 16, Issue 2, 2010, Pages 191-197

  Emamaullee, Juliet A ^a   Edgar, Ryan ^a   Toso, Christian ^a   Thiesen, Aducio ^a   Bain, Vincent ^a   Bigam, David ^a   Kneteman, Norman ^a   Shapiro, A M James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; IMMUNOFLUORESCENCE TEST; LIVER BIOPSY; LIVER HEMANGIOENDOTHELIOMA; LIVER SURGERY; LIVER TRANSPLANTATION; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BIOPSY; DISEASE-FREE SURVIVAL; FEMALE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 75449108650     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21964     Document Type: Article

References (15)

1. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006;107:2108-2121.
2. Lerut JP, Orlando G, Adam R, Schiavo M, Klempnauer J, Mirza D, et al. The place of liver transplantation in the treatment of hepatic epithelioid hemangioendothelioma: report of the European liver transplant registry. Ann Surg 2007;246:949-957; discussion 57.
3. Breen EC. VEGF in biological control. J Cell Biochem 2007;102:1358-1367.
4. Miller MA, Sandler AD. Elevated plasma vascular endothelial growth factor levels in 2 patients with hemangioendothelioma. J Pediatr Surg 2005;40:e17-e19.
5. Szymik-Kantorowicz S, Partyka L, Dembinska-Kiec A, Zdzienicka A. Vascular endothelial growth factor in monitoring therapy of hepatic haemangioendothelioma. Med Pediatr Oncol 2003;40:196-197.
6. He M, Das K, Blacksin M, Benevenia J, Hameed M. A translocation involving the placental growth factor gene is identified in an epithelioid hemangioendothelioma. Cancer Genet Cytogenet 2006;168:150-154.
7. Theurillat JP, Vavricka SR, Went P, Weishaupt D, Perren A, Leonard-Meier C, et al. Morphologic changes and altered gene expression in an epithelioid hemangioendothelioma during a ten-year course of disease. Pathol Res Pract 2003;199:165-170.
8. Makhlouf HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999;85:562-582.
9. Rodriguez JA, Becker NS, O'Mahony CA, Goss JA, Aloia TA. Long-term outcomes following liver transplantation for hepatic hemangioendothelioma: the UNOS experience from 1987 to 2005. J Gastrointest Surg 2008;12:110-116.
10. Nudo CG, Yoshida EM, Bain VG, Marleau D, Wong P, Marotta PJ, et al. Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol 2008;22:821-824.
11. Statistical data reported by the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network in 2009. Available at: http:// www.unos.org. Accessed September 2009.
12. Belmont L, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 2008;3:557-558.
13. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
14. Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol 2008;49:1-5.
15. Huynh H, Chow PK, Palanisamy N, Salto-Tellez M, Goh BC, Lee CK, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 2008;49:52-60.